45 CFR § 180 compliance
C · 70
This hospital published part of what § 180 requires.
●Machine-readable file published
○Gross / standard charges
○Discounted cash price
●Payer-specific negotiated rates
●Min / max negotiated charges
●Free, public, no login required
Procedures listed
22,122
Insurances with rates
30
CPT / HCPCS codes
19,617
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| J1299 | Eculizumab (Soliris) 1,200 mg in sodium chloride 0.9 % 240 mL infusion | $277,410 | $72,127 | $66,578 | $194,187 | 8 |
| J1299 | Eculizumab (Soliris) 1,200 mg in sodium chloride 0.9 % 240 mL infusion | $277,410 | $72,127 | — | — | 0 |
| A9543 | HC MED: YTTRIUM Y-90 IBRITUMOMAB TIUXETAN, THERAPEUTIC, PER TMT DOSE, UP TO 40 MCI | $158,722 | $41,268 | $19,047 | $134,914 | 48 |
| J9043 | Cabazitaxel (Jevtana) 46.3 mg in sodium chloride 0.9 % 250 mL chemo infusion | $139,457 | $36,259 | $195 | $118,538 | 50 |
| J9272 | dostarlimab-gxly (Jemperli) 500 mg in sodium chloride 0.9 % 250 mL chemo infusion | $127,906 | $33,256 | $210 | $108,720 | 50 |
| J9271 | pembrolizumab (Keytruda) 200 mg in sodium chloride 0.9 % 100 mL infusion | $125,409 | $32,606 | $53.69 | $106,598 | 50 |
| J9022 | atezolizumab (Tecentriq) 1,200 mg in sodium chloride 0.9 % 250 mL infusion | $123,218 | $32,037 | $77.18 | $104,735 | 50 |
| J9119 | cemiplimab-rwlc (Libtayo) 350 mg in sodium chloride 0.9 % 100 mL infusion | $116,154 | $30,200 | $26.29 | $98,731 | 50 |
| J9144 | Daratumumab-Hyaluronidase-fihj (Darzalex-Faspro) 1800-30000 MG-UT/15ML injection 1,800 mg | $112,400 | $29,224 | $42.6 | $95,540 | 50 |
| J9317 | sacituzumab govitecan (Trodelvy) 720 mg in sodium chloride 0.9 % 500 mL infusion | $109,021 | $28,345 | $33.04 | $92,667 | 50 |
| J9301 | obinutuzumab (Gazyva) 1,000 mg in sodium chloride 0.9 % 250 mL infusion | $95,691 | $24,880 | $66.43 | $81,338 | 50 |
| J1932 | lanreotide acetate (Somatuline) 120 MG/0.5ML depot injection 120 mg | $94,547 | $24,582 | $28.6 | $80,365 | 50 |
| J9299 | nivolumab (Opdivo) 216 mg in sodium chloride 0.9 % 100 mL infusion | $84,451 | $21,957 | $27.39 | $71,783 | 50 |
| J9308 | Ramucirumab (Cyramza) 500 mg in sodium chloride 0.9 % 250 mL chemo infusion | $79,782 | $20,743 | $63.45 | $67,814 | 50 |
| 33270 | HC 33270 INS/REPL PRM SQ IMPLT DFIB W/SQ ELECTRODE | $74,014 | $19,244 | $1,589 | $88,465 | 47 |
| J2353 | octreotide (SandoSTATIN LAR) IM injection kit 30 mg | $73,494 | $19,109 | $204 | $62,470 | 50 |
| J9306 | Pertuzumab (Perjeta) 420 mg in sodium chloride (Visiv) 0.9 % 250 mL infusion | $72,516 | $18,854 | $12.88 | $61,638 | 50 |
| 37227 | HC 37227 STENT & ATH W/WO PTA FEM/POP | $69,716 | $18,126 | $1,880 | $59,259 | 47 |
| C2616 | HC C2616 BRACHY SOURCE YTTRIUM 90 UNSTR | $69,101 | $17,966 | $8,292 | $58,736 | 52 |
| J9217 | leuprolide (Lupron) injection 22.5 mg | $68,458 | $17,799 | $153 | $58,189 | 50 |
| J2506 | pegfilgrastim (Neulasta Onpro) injection kit 6 mg | $68,236 | $17,741 | $18.63 | $58,001 | 50 |
| 50590 | HC 50590 LITHOTRIPSY KIDNEY | $68,051 | $17,693 | $553 | $57,843 | 47 |
| 93654 | HC 93654 EP & ABLATE VENTRIC TACHY | $67,652 | $17,590 | $2,761 | $57,504 | 47 |
| J7165 | Prothrombin Complex Human-lans (Balfaxar) injection 2,000 Units 80 mL | $66,982 | $17,415 | $1.68 | $56,934 | 50 |
| 33263 | HC 33263 RMVL/REPL ICD GEN, DUAL LEAD | $63,909 | $16,616 | $1,589 | $64,463 | 47 |
| 33264 | HC 33264 RMVL/REPL ICD GEN, MULTI LEAD | $63,909 | $16,616 | $1,589 | $90,270 | 47 |
| 33231 | HC 33231 INS ICD GEN W/EXIST MULT LEADS | $62,887 | $16,351 | $1,589 | $90,270 | 47 |
| 33262 | HC 33262 RMVL/REPL ICD GEN, SINGLE LEAD | $59,743 | $15,533 | $1,589 | $64,463 | 47 |
| 22514 | HC 22514 PERQ VERT AGMNTJ CAVITY CRTJ UNI/BI CANNULJ LMBR | $57,344 | $14,909 | $483 | $48,742 | 47 |
| J0875 | dalbavancin HCl (Dalvance) 1,500 mg in dextrose 5 % 500 mL IVPB | $56,747 | $14,754 | $14.54 | $48,235 | 50 |
| 93656 | HC 93656 TX ATRIAL FIB PULM VEIN ISOL | $56,367 | $14,655 | $2,770 | $53,984 | 47 |
| 93653 | HC 93653 EP & ABLATE SUPRAVENT ARRHYT | $52,542 | $13,661 | $2,062 | $53,984 | 47 |
| J7189 | coagulation factor VIIa (recomb) (NovoSeven RT) injection 1,688 mcg | $50,401 | $13,104 | $2.02 | $42,841 | 50 |
| 37235 | HC 37235 TIB/PER., UNILATERAL, EA ADDIT | $49,789 | $12,945 | $1,230 | $49,789 | 32 |
| 92941 | HC 92941 COR REVASC W AMI 1 VSL | $49,115 | $12,770 | $2,636 | $49,115 | 36 |
| C9606 | HC C9606 D-E COR REVASC W AMI 1 VSL | $49,115 | $12,770 | $2,086 | $49,115 | 36 |
| J9034 | bendamustine (Bendeka) 184.5 mg in sodium chloride 0.9 % 50 mL chemo infusion | $48,658 | $12,651 | $12.53 | $41,359 | 50 |
| 33274 | HC 33274 TRNSCTH INSJ/RPLC PERM LDLS PM RT VENTR W/IMG | $46,413 | $12,067 | $483 | $44,766 | 47 |
| 92943 | HC 92943 COR REVASC CHRO 1 VSL | $45,782 | $11,903 | $3,104 | $38,915 | 47 |
| C9607 | HC C9607 D-E COR REVASC CHRO 1 VSL | $45,782 | $11,903 | $3,104 | $43,905 | 47 |
| Q5127 | Pegfilgrastim-fpgk (Stimufend) injection 6 mg | $45,720 | $11,887 | $278 | $38,862 | 50 |
| 92928 | HC 92928 COR STENT ANGIO 1 VSL | $45,531 | $11,838 | $3,104 | $38,701 | 47 |
| 33289 | HC 33289 TCAT IMPL WRLS P-ART PRS SNR L-T HEMODYN MNTR | $45,486 | $11,826 | $483 | $85,543 | 47 |
| 92937 | HC 92937 COR REVASC BYP GRFT 1 VSL | $44,520 | $11,575 | $3,104 | $37,842 | 47 |
| C9604 | HC C9604 D-E COR REVASC BYP GRFT 1 VSL | $44,520 | $11,575 | $3,104 | $37,842 | 47 |
| Q5111 | pegfilgrastim-cbqv (Udenyca Onbody) subcutaneous injection 6 mg | $44,389 | $11,541 | $126 | $37,730 | 50 |
| C9600 | HC C9600 D-E COR STENT ANGIO 1 VSL | $43,255 | $11,246 | $3,104 | $36,767 | 47 |
| 37226 | HC 37226 STENT FEM/POP W/WO PTA | $43,174 | $11,225 | $1,880 | $36,698 | 47 |
| C9773 | HC C9773 REVASC LITHOTR-STENT TIB/PER | $42,701 | $11,102 | $1,880 | $46,835 | 47 |
| 93460 | HC 93460 RHC, LHC, & CORONARY | $41,652 | $10,830 | $2,998 | $35,404 | 47 |
Showing top 50 of 22,122 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.